| Literature DB >> 26306536 |
Bin Song1, Jia Liu, Xiaoli Feng, Limin Wei, Longquan Shao.
Abstract
As the rapid development of nanotechnology in the past three decades, titanium dioxide nanoparticles (TiO2 NPs), for their peculiar physicochemical properties, are widely applied in consumer products, food additives, cosmetics, drug carriers, and so on. However, little is known about their potential exposure and neurotoxic effects. Once NPs are unintentionally exposed to human beings, they could be absorbed, and then accumulated in the brain regions by passing through the blood-brain barrier (BBB) or through the nose-to-brain pathway, potentially leading to dysfunctions of central nerve system (CNS). Besides, NPs may affect the brain development of embryo by crossing the placental barrier. A few in vivo and in vitro researches have demonstrated that the morphology and function of neuronal or glial cells could be impaired by TiO2 NPs which might induce cell necrosis. Cellular components, such as mitochondrial, lysosome, and cytoskeleton, could also be influenced as well. The recognition ability, spatial memory, and learning ability of TiO2 NPs-treated rodents were significantly impaired, which meant that accumulation of TiO2 NPs in the brain could lead to neurodegeneration. However, conclusions obtained from those studies were not consistent with each other as researchers may choose different experimental parameters, including administration ways, dosage, size, and crystal structure of TiO2 NPs. Therefore, in order to fully understand the potential risks of TiO2 NPs to brain health, figure out research areas where further studies are required, and improve its bio-safety for applications in the near future, how TiO2 NPs interact with the brain is investigated in this review by summarizing the current researches on neurotoxicity induced by TiO2 NPs.Entities:
Year: 2015 PMID: 26306536 PMCID: PMC4549355 DOI: 10.1186/s11671-015-1042-9
Source DB: PubMed Journal: Nanoscale Res Lett ISSN: 1556-276X Impact factor: 4.703
Fig. 1A diagram of the blood–brain barrier structure
Fig. 2A simple diagram of nose–brain pathway after intranasal administration
Fig. 3Substance exchange between the mother and fetus through placenta barrier
Fig. 4A simple diagram of bio-distribution of Ti after TiO2 NPs exposure
Bio-distribution of TiO2 NPs after rat/mice were administrated by different routes
| Crystal type | Animal | Administration | Parameters/dose | Bio-distribution | Reference |
|---|---|---|---|---|---|
| Both anatase and rutile forms (70/30) | Male Wistar rats | Intravenous injection | 20–30 nm; no surface coating; 5 mg/kg body weight (BW); single injection | Liver, spleen, lung, and kidney detected; blood cells, plasma, lymph nodes, and brain not detected | [ |
| Both anatase and rutile forms (80/20) | BALB/c female mice | Subcutaneous (s.c.) injection | Hydrodynamic diameters ranging from 114 to 122 nm; 5600 mg/kg BW; 2 consecutive days | Liver, lymph node and spleen detected; brain not detected | [ |
| Intravenous (i.v.) injection | Hydrodynamic diameters ranging from 114 to 122 nm; 560 mg/kg BW; 2 consecutive days | Lung, liver, lymph node, spleen and kidney detected; brain not detected | |||
| Rutile | Male mice | Intravenous injection | Primary particle diameter 15 nm, secondary particle size 120 nm; 1813 μg/animal | Liver, kidney, blood detected; brain not detected | [ |
| Rutile | CD-1 (ICR) female mice | Intranasal instillation | 80 nm; 50 mg/kg BW; every other day for 30 days | Lung and brain detected; liver, heart, and spleen not detected | [ |
| Anatase | 155 nm; 50 mg/kg BW; every other day for 30 days | ||||
| Degussa P25 | Rats | Intravenous administration | 21 nm; spherical; 0.95 mg/kg BW; single injection | Liver (highest), spleen, lung, kidney, heart and blood detected; brain not detected | [ |
| Anatase 80: 20 rutile | Sprague–Dawley rats | Oral administration | 21 nm; spherical; 260.4, 520.8, and 1041.5 mg/kg/day BW; every day for 13 weeks (7 days/week) | Low absorption in other organs and brain not detected | [ |
| Anatase | Male Kunming mice | Inhalation exposure | 20 nm; steady concentration (6.34 ± 0.22 mg m−3); 8 h per day for 3 weeks | Lungs, liver, blood, and urine detected; kidney and brain not detected | [ |
Toxic effects of TiO2 NPs on CNS in in vivo studies
| Crystal type | Animals | Cell type | Parameters/dose | Main findings | Reference |
|---|---|---|---|---|---|
| Rutile 80 nm anatase 155 nm | CD-1 (ICR) female mice | Nasal instillation | 500 μg; every other day for 30 days | Ti contents detected in the brain; GFAP-positive cell, CAT, SOD, MDA, protein carbonyls, AChE activities, glutamic acid, and NO increased | [ |
| Anatase bulk | CD-1 (ICR) female mice | Delivered to the abdominal cavity | 5 nm; 5, 10, 50, 100, 150 mg/kg BW; every day for 14 days | Ti contents detected in brain; O2, H2O2, MDA, NOS, NO increased; Glu contents, antioxidative enzymes, non-enzymatic antioxidant contents, and AChE activity decreased | [ |
| Anatase | CD-1 male mice | Intranasal administration | 5–6 nm; 2. 5, 5, 10 mg/kg BW. every day for 90 days | Ti contents detected in brain; no daily behavioral changes; O2, H2O2, MDA, protein carbonyl, 8-OHdg, p38, JNK, NF-κB, Nrf-2, and HO-1 increased | [ |
| Anatase | Sprague–Dawley rats (male and female) | Subcutaneous injection | 5 nm; 500 μl (1 μg/μl) on GD 6, 9, 12, 15, and 18 | CAT, GSH-PX, and T-AOC decreased; MDA and 8-hydroxydeoxyguanosine (8-OHdG) increased | [ |
| Rutile 80 nm anatase 155 nm | CD-1 (ICR) female mice | Intranasal instillation | 500 μg; every other day for 30 days; evaluated at 2, 10, 20, and 30 days of post-instillation time points | Ti contents detected in brain; GSH-Px, GST, SOD and GSH not changed; MDA, TNF-α and IL-1β increased | [ |
| Anatase | CD-1 (ICR) female mice | Intranasal administration | 5–6 nm; 2.5, 5, 10 mg/kg BW; every day for 90 days | TLR2, TLR4, TNF-α, IKK1, IKK2, NF-κB, NF-κBP52, NF-κBP65, NIK, and IL-1β increased; spatial recognition memory and locomotor activity affected | [ |
| Rutile | Male C57BL/6 mice | Intraperitoneal injection | Fine (<1 μm), ultrafine (21 nm); 40 mg/kg BW; one injection 30 min after LPS or vehicle injection | IL-1β, TNF-α, iNOS, ROS production, and OX-42 enhanced by ultrafine TiO2 in the LPS-stimulated group | [ |
| Anatase | CD-1 (ICR) female mice | Intragastric administration | 6.5 nm; 5, 10, 50 mg/kg BW; every day for 60 days | Ti contents in the hippocampus increased; caspase-9, caspase-3, Bax, cytochrome c, O2 and H2O2 upregulated; Bcl-2, SOD, CAT, APx, and GSH-Px reduced | [ |
| Anatase | CD-1 female mice | Nasal administration | 5–6 nm; 2.5, 5, 10 mg/kg BW; every day for 90 days | NR2A, NR2B, CREB-1, CREB-2, FosB/DFosB, CaMKIV, and pCREB decreased | [ |
| Anatase | CD-1 female mice | Intragastric administration | 5 nm; 5, 10, 50 mg/kg BW; every day for 60 days | Ti contents in brain upregulated; reduction in the activities of Na+/K+-ATPase, Ca2+-ATPase, Ca2+/Mg2+-ATPase; Ache, Glu, and NO elevated; NE, DA, DOPAC, 5-HT, and 5-HIAA reduced | [ |
| Anatase | Pregnant ICR mice | Subcutaneous injection | 2570 nm; 100 μg, injection on GD 6, 9, 12, 15 | Genes related with cell death, apoptosis, oxidative stress, inflammation and neurotransmitters changed | [ |
| Rutile | Pregnant BALB/c mice | Intravenous injection | 35 nm; 0.8 mg, injections on GD 16 and 17 | Lower uterine weights and smaller fetuses; fetal resorption and retarded fetal growth | [ |
| Anatase | Pregnant Wistar rats | Intragastric administration | 10 nm; 100 mg/kg BW, every day from GD 2 to 21 | Ti contents elevated and Ki-67-positive cells reduced; learning and memory in offspring disrupted | [ |
Toxic effects of TiO2 NPs on CNS in in vitro studies
| Crystal type | Cell type | Parameters/dose | Main findings | Reference |
|---|---|---|---|---|
| Unknown | Primary microglia from Sprague–Dawley rats and PC12 | 20 nm; 0.25 or 0.5 mg/ml; 24 or 48 h | NO, iNOS, MCP-1, MIP-1α, and NF-κB binding activity increased and Th inhibited in microglia; marked cytotoxicity in PC12 after incubation with supernatant of NPs-treated microglia | [ |
| Anatase | PC12 | Average 21 nm (range from 20 to 50 nm); 1, 10, 50, 100 μg/ml; incubated for 6, 12, 24, 48 h | Viability of cells decreased except 1 μg/ml group; DCF-positive cells and ratio of PC12 apoptosis elevated | [ |
| Anatase and rutile | PC12 | 20 nm; 25, 50, 100, 200 μg/ml for 24 h | Apparent cytotoxicity; GSH, SOD, and mitochondrial membrane potential decreased; MDA and G2/M phase cells elevated; p-JNK, JNK, p-c-Jun, Jun, p-P53, p53, p21 GADD45, Bcl-2, and Bax disrupted | [ |
| Anatase (96 %) | C6 U373 | 40–200 nm; 2.5, 5, 10, 20, 40 μg/ml; 24, 48 or 96 h | Apoptosis; cellular proliferation depressed; morphology and cytoskeleton changed; reduction in immune-location of F-actin fibers | [ |
| Unknown | C6 U373 | 50 nm; 20 μg/cm2 for 2, 4, 6, 24, 48, 72 h | Imbalance in GPx, SOD and catalase; fluorescence of cis-parinaric acid and Rh123 downregulated; H2DCFDA and MitoTracker Green FM staining elevated | [ |
| Rutile coated by SiO2 | Mouse NSCs line C17.2 | 80–100 nm; 50, 100, 150, 200, 250 μg/ml exposed for 12, 24, 36, 48, 60, 72 h, or 7 days | Inhibition on cellular proliferation; β-tubulin positive cells detected; Cx43 elevated; PKCε reduced | [ |
| Unknown | HCECs (human cerebral endothelial cells) | 21 nm; 2 mg/ml; 0.12, 0.6, 3, 15, 75 μg/cm2 for 4, 24, 48, or 72 h | Significant cytotoxicity, ROS production, and marked DNA damage detected; cathepsin D and LC3-II upregulated | [ |
| Anatase | Primary hippocampal neurons | 5 nm; 5, 15, 30, 40, 50 μg/ml for 6, 12, 24, or 48 h | Cell viabilities and MMP reduced; LDH activities, apoptotic rate, and cytoplasmic Ca2+ elevated; ultrastructure of cells altered; apoptotic cytokine disturbed | [ |
| Anatase (S) Anatase (80 %) + rutile (D) | Human SHSY5Y neuronal cells | 25 nm; 20, 40, 60, 80, 100, 120, 140, 160 μg/ml for 3, 6, 24 h | No cytotoxicity; cell cycle changed; apoptotic cells elevated; genotoxicity detected; no oxidative damage | [ |
| Anatase | Human neural stem cell line | 80 nm; 0.01, 0.1, 1 mg/ml for 7 days | Morphology changed; mitochondrial activity not changed; Nestin, neurofilament heavy polypeptide, and high mobility group AT-hook 1 elevated | [ |